Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 6/20 | 0.42 |
| ▸ | CPA3 | P15088 | 3/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL252900 | 0.81 | CYP1A2 (0.68) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL9007628 | 0.81 | CYP1A2 (0.68) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL629350 | 0.81 | CYP1A2 (0.68) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL11324047 | 0.79 | CYP1A2 (0.53) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL2065619 | 0.79 | CYP1A2 (0.53) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL2361534 | 0.79 | CYP1A2 (0.53) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL8144720 | 0.79 | CYP1A2 (0.53) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL435251 | 0.76 | CYP1A2 (0.50) | CYP1A2CYP2C19 | |
| SCHEMBL6542596 | 0.76 | HDAC3 (0.52) | CYP1A2MME | |
| SCHEMBL7319419 | 0.75 | CYP1A2 (0.49) | CYP1A2CPA1CPA3FOLH1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1305015-B1 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8324190-B2 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | Temple University—Of the Commonwealth System of Higher Education (US) | 2012-12-04 | — | — | US | disclosed |
| EP-1487428-B1 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2359819-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | Temple University - Of The Commonwealth System of Higher Education (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-1223923-B1 | UNSATURATED ARYL SULFONES FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | UNIV TEMPLE (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-1328511-B1 | SUBSTITUTED (E)-STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090281066-A1 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7598232-B2 | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7595347-B2 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1370253-B8 | USE OF ALPHA, BETA UNSATURATED ARYL SULFONES FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY | UNIV TEMPLE (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1305015-A1 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030060505-A1 | Method for protecting cells and tissues from ionizing radiation toxicity with alpha, beta unsaturated aryl sulfones | ONCONOVA THERAPEUTICS, INC. | 2003-03-27 | — | — | US | disclosed |
| US-20030036536-A1 | Useful as antiproliferative agents, including, for example, anticancer agents | REDDY E PREMKUMAR (US) | 2003-02-20 | — | — | US | disclosed |
| US-6486210-B2 | SUCH AS ENANTIOMORPHS OF 4-FLUOROSTYRYL-2,3,4,5,6-PENTAFLUOROBENZYLSULFONE; ANTIPROLIFERATIVE/ANTICANCER AGENTS | Temple University—Of the Commonwealth System of Higher Education | 2002-11-26 | — | — | US | disclosed |
| WO-2002069892-A2 | METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020115643-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-08-22 | — | — | US | disclosed |
| EP-1223923-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002028828-A1 | SUBSTITUTED (E)-STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-04-11 | — | — | WO | disclosed |
| WO-2001078712-A1 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001026645-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036536-A1 | Useful as antiproliferative agents, including, for example, anticancer agents | MKI67, MCL1, CCNA1 | CYP1A2 4230/4885CPA1 3131/4885CPA3 4455/4885 |
| US-20030060505-A1 | Method for protecting cells and tissues from ionizing radiation toxicity with alpha, beta unsaturated aryl sulfones | ARSA, SULT2A1, CYP2S1 | CYP1A2 264/4885CPA1 1338/4885CPA3 2650/4885 |
| US-20090281066-A1 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | CCNY, CCND2, ETV6 | CYP1A2 1605/4885CPA1 3955/4885CPA3 3995/4885 |
| US-20020115643-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | HCCS, CCNO, HRAS | CYP1A2 4786/4885CPA1 3569/4885CPA3 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.